News

GSK chief defends profits made on back of swine flu crisis

BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c2385 (Published 29 April 2010) Cite this as: BMJ 2010;340:c2385
  1. Helen Mooney
  1. 1London

    Andrew Witty, chief executive of global drug company GlaxoSmithKline, has denied accusations that the company profiteered during the swine flu crisis. Last year the company made a pre-tax profit of more than $13bn (£8.5bn; €9.8).

    In an interview on the BBC’s World Have Your Say programme on 26 April Mr Witty denied that the company had “charged the whole world” for a vaccine that may not have been necessary.

    “We have spent $2.5bn over the last seven years preparing for this situation, I think we charged a very …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe